Lu,
This one was put on by the local chapter. If you join your local MS chapter, you should be made aware of when they are hosting them.
Also, the pharm reps were in attendance w/handouts and to answer questions, etc.
I'm trying to hit up the ones now where the Drs are directly associated with the center. This one was the director. It's a bit more difficult, because they are futher inbetween (like I said, the one I saw in the past, didn't impress me at all and wasn't associated w/the center).
Saveone! Thank you so much! I need to write more clearly lol. This should be available very soon and sounded to me to be very, very promising for those w/difficulty walking. It would be prescribed quite like things like Baclofen, etc.,
Shell I was intrigued by the medication so I googled it....Fampridine came up. here is the excerpt.
Fampridine-SR ("4-aminopyridine", "4-AP", “fampridine”) is an investigational oral, sustained-release formulation of 4-aminopyridine. In laboratory studies fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged.
Clinical History of Fampridine-SR in SCI
from http://www.acorda.com/pipeline_fampridine_sci1.asp
In 2004, Acorda completed two Phase 3 clinical trials of Fampridine-SR in people with spinal cord injury (SCI). These studies did not reach statistical significance in their primary endpoints, reduction of spasticity (as measured by the Ashworth score) and improvement of participant's Subject Global Impression (SGI) rating.
Acorda recently completed a Phase 3 clinical study of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with all types of MS. For a copy of the press release and study results, please click here.
To learn about Fampridine-SR’s mechanism of action click here.
Hi Shell,
I vaguely remember seeing a post on this from one of the national orgs. or a drug company - can you tell us the sponsor so we can search for a session in our area?
be well,
Lu